|
pubmed:abstractText |
New intermittent regimens with bisphosphonates such as oral ibandronate, and maybe annual intra-venous zoledronate, will be useful additions to the treatment of post-menopausal osteoporosis. Strontium ranelate is a new molecule that both inhibits bone resorption and stimulates bone formation, with proven efficacy to reduce fracture incidence. Teriparatide (1-34 fragment of parathyroid hormone), using daily subcutaneous injections, has also proven its efficacy to decrease vertebral and peripheral fracture risk in postmenopausal osteoporotic women. In the next five years, new SERMs and inhibitors of RANK-ligand might be new treatment options.
|
|
pubmed:affiliation |
Service de rhumatologie et de pathologie osseuse et Inserm U403, pavillon F, hôpital Edouard-Herriot, 5, place Arsonval, 69437 Lyon 03, France. chapurlat@lyon.inserm.fr
|
